Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals' Other Non-Current Liabilities history spans 14 years, with the latest figure at $269000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 14.47% year-over-year to $269000.0; the TTM value through Dec 2025 reached $269000.0, up 14.47%, while the annual FY2025 figure was $260000.0, 12.55% up from the prior year.
  • Other Non-Current Liabilities reached $269000.0 in Q4 2025 per ENTA's latest filing, up from $260000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.5 million in Q3 2021 to a low of $224000.0 in Q1 2024.
  • Average Other Non-Current Liabilities over 5 years is $573150.0, with a median of $411000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: soared 87.59% in 2021, then plummeted 83.77% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $520000.0 in 2021, then fell by 20.38% to $414000.0 in 2022, then skyrocketed by 56.76% to $649000.0 in 2023, then tumbled by 63.79% to $235000.0 in 2024, then increased by 14.47% to $269000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Other Non-Current Liabilities are $269000.0 (Q4 2025), $260000.0 (Q3 2025), and $252000.0 (Q2 2025).